Sarepta Therapeutics Stock Forecast, Price & News

Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

Is Sarepta Therapeutics a buy right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sarepta Therapeutics stock.
View analyst ratings for Sarepta Therapeutics or view top-rated stocks.

How has Sarepta Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SRPT shares have decreased by 23.6% and is now trading at $78.50.
View which stocks have been most impacted by COVID-19.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Sarepta Therapeutics.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) issued its quarterly earnings data on Wednesday, November, 3rd. The biotechnology company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($1.86) by $1.26. The biotechnology company earned $189.41 million during the quarter, compared to analysts' expectations of $170.13 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 86.35% and a negative net margin of 75.30%. During the same quarter in the prior year, the company posted ($2.50) EPS.
View Sarepta Therapeutics' earnings history.

What price target have analysts set for SRPT?

20 brokers have issued 12 month target prices for Sarepta Therapeutics' shares. Their forecasts range from $90.00 to $215.00. On average, they expect Sarepta Therapeutics' share price to reach $130.47 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price.
View analysts' price targets for Sarepta Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the following people:

• Douglas S. Ingram, President, Chief Executive Officer & Director (LinkedIn Profile)
• Ian M. Estepan, Executive VP, Chief Financial & Accounting Officer
• Louise Rodino-Klapac, Chief Scientific Officer
• Dallan Murray, Chief Commercial Officer & Senior Vice President
• Ryan E. Brown, Secretary, Senior Vice President & General Counsel

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics CEO Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among Sarepta Therapeutics' employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Sarepta Therapeutics' key competitors?

Some companies that are related to Sarepta Therapeutics include Genmab A/S (GNMSF), Genmab A/S (GMAB), Shiseido (SSDOY), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Takeda Pharmaceutical (TKPYY), Catalent (CTLT), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Elanco Animal Health (ELAN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF) and Dr. Reddy's Laboratories (RDY).
View all of SRPT's competitors.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (8.50%), Sands Capital Management LLC (6.97%), BlackRock Inc. (5.47%), Capital Research Global Investors (2.92%), Point72 Asset Management L.P. (2.12%) and Wellington Management Group LLP (1.61%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Richard Barry and Sandesh Mahatme.
View institutional ownership trends for Sarepta Therapeutics.

Which major investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Capital Research Global Investors, Citigroup Inc., Macquarie Group Ltd., Voloridge Investment Management LLC, Renaissance Technologies LLC, Wellington Management Group LLP, and Sands Capital Management LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Hans Lennart Rudolf Wigzell, Joseph Bratica, and M Kathleen Behrens.
View insider buying and selling activity for Sarepta Therapeutics or view top insider-selling stocks.

Which major investors are buying Sarepta Therapeutics stock?

SRPT stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bellevue Group AG, Janus Henderson Group PLC, Camber Capital Management LP, Two Sigma Investments LP, Casdin Capital LLC, Bank of Nova Scotia, and Farallon Capital Management LLC. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, and Louise Rodino-Klapac.
View insider buying and selling activity for Sarepta Therapeutics or or view top insider-buying stocks.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $78.50.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics has a market capitalization of $6.84 billion and generates $540.10 million in revenue each year. The biotechnology company earns $-554.13 million in net income (profit) each year or ($6.12) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

Sarepta Therapeutics employs 866 workers across the globe.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.

Where are Sarepta Therapeutics' headquarters?

Sarepta Therapeutics is headquartered at 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (857) 242-4000, via email at [email protected], or via fax at 425-354-5038.